Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
Clicks: 343
ID: 116578
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
342 views
11 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Sustaining clinical remission is an important treatment goal in moderate-to-severe UC. This post hoc exploratory analysis assessed the long-term efficacy of vedolizumab in the subset of patients with UC in the GEMINI 1 study who were in clinical remission ...
| Reference Key |
o’byrne2019inflammatorysustained
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Brian G Feagan, Stefan Schreiber, Douglas C Wolf, Jeffrey L Axler, Arpeat Kaviya, Alexandra James, Rebecca I Curtis, Parnia Geransar, Andreas Stallmach, Robert Ehehalt, Bernd Bokemeyer, Javaria Mona Khalid, Sharon O’Byrne;Brian G Feagan;Stefan Schreiber;Douglas C Wolf;Jeffrey L Axler;Arpeat Kaviya;Alexandra James;Rebecca I Curtis;Parnia Geransar;Andreas Stallmach;Robert Ehehalt;Bernd Bokemeyer;Javaria Mona Khalid;Sharon O’Byrne; |
| Journal | inflammatory bowel diseases |
| Year | 2019 |
| DOI |
10.1093/ibd/izy323
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.